CONCLUSIONS
Au terme de cette étude, nous concluons que les
maladies rhumatismales sont fréquentes et variées dans la zone de
santé de Gombe-Matadi.
Elles sont dominées par l'arthrose, les maladies
abarticulaires et les rhumatismes inflammatoires chroniques.
Ces affections sont surtout rencontrées chez des
individus approchant la cinquantaine, avec une prédominance
féminine.
Quelques différences démographiques ou cliniques
ont été constatées pour certaines pathologies par rapport
aux données de la littérature.
PERSPECTIVES
Ce travail ouvre les perspectives de recherche
suivantes :
· Déterminer le profil immunologique et
génétique de la population enquêtée ;
· Réaliser des études des
cohortes ;
· Dégager quelques indicateurs utiles en vue de
proposer aux décideurs de les insérer dans le système
national d'information sanitaire ;
· Dégager un programme de prise en charge dans la
communauté enquêtée.
RECOMMANDATIONS
Aux autorités de la Zone de
Santé :
· de Considérer les affections rhumatismales comme
un véritable problème de santé publique ;
· de proposer un paquet minimum d'activités pour
faciliter la prévention à 3 niveaux :
- primaire pour aider la population à réduire
l'exposition aux facteurs de risque dans l'environnement par
l'éducation;
- secondaire en vue d'offrir une prise en charge
correcte des rhumatisants par le médecin (la formation continue);
- tertiaire en vue de planifier et d'assurer l'administration
et le suivi de soins spéciaux capable de réduire ou de minimiser
l'handicap par le rhumatologue.
REFERENCES
1. Cofer, Precis de Rhumatologie, Masson, Paris 2002.
2. Cush JJ, Lipsky PE. Approche des affections articulaires
et musculosquelettiques. In Médecine interne. Harrison. McGraw-Hil.
2000. pp 2220-7.
3. Rat A, El Adssi H. Epidémiologie des maladies
rhumatismales. ECM Appareil locomoteur; avril 2013; 8: 2.
4. Minaur N, Jackoby RK, Cosh JA, Taylor G, Rasker JJ.
Outcome after 40 years with rheumatoid arthritis; prospective study of function
disease activity and mortality.JRheumatolSuppl. 2004 Mar; 69:3-8.
5. Guillemin F.La charge que représentent les maladies
rhumatismales : l'invalidité et ses conséquences. Rhumatologie en
Europe 1998 ; 27/1 : 11-4.
6. Woolf AD. The Bone and Joint Decade 2000-2010. Ann Rheum
Dis 2000 ; 59:81-2.
7. Minaur N, Sawyers S, Paker J, Darmawan J (2004) Rheumatic
disease in an Australian Aboriginal community in North Queensland, Australia. A
WHO-ILAR COPCORD survey. J Rheumatol 31:965-72.
8. Mekes CJ. La polyarthrite rheumatoid de l'adulte. Ed.
Masson 2004, Paris, France.
9. Silman AJ, Hochberg MC. Epidemiology of rheumatic
diseases.2nd Ed. Oxford: Oxford University Press, 2001,pp.377
10. Murphy L, Helmick CG. The impact of osteoarthritis in the
United States: A population health perspective: A population-based review of
the fourth most common cause of hospitalization in U.S.adults.Orthop Nurs
2012;31(2):85-91.
11. Zeng QY, Chen R, Xiao ZY et al (2004) Low prevalence of
knee and back pain in southeast China; the Shantou COPCORD study J Rheumatol
31: 2439-43.
12. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD (1992)
Epidemiology of rheumatic diseases in rural and urban populations in Indonesia:
a World Health Organization International League Against Rheumatism COPCORD
study, stage I, phase 2. Ann Rheum Dis 51:525-8.
13. Chopra A, Saluja M, Patil J, Tandale HS (2002) Pain and
disability, perceptions and beliefs of a rural Indian population: A WHO-ILAR
COPCORD study. WHO-International League of Associations for Rheumatology.
Community oriented program for control of rheumatic diseases. J Rheumatol
29:614-21.
14. Chopra A, Patil J, Billemplely V, Relwani J, Tandle HS
(2001) Prevalence of rheumatic diseases in a rural population in Western India:
a WHO-ILAR COPCORD study. J Ass Physicians India 49:240-6.
15. Forghanizadeh J, Abhari R, Piroozian M et al (1995)
Prevalence of rheumatic disease in Fasham. Journal of Iran University of
Medical Sciences 3:132-142.
16. Davatchi F, Jamshidi AR, Tehrani-Banihashemi A, Darmawan J
(2006) WHO-ILAR COPCORD pilot study in Tehran, Iran. J Rheumatol 33:1774.
17. Davatchi F, Jamshidi AR, Tehrani-Banihashemi A et al
(2004) Iran COPCORD study. In : APLAR 2004 Proceedings Book, Future in
Rheumatology : Form Bench to Bedside, 11th Asia Pacific League of
Associations for Rhumatology Congress, MediMedia, Korea, pp89-91.
18. Davatchi F, Jamshidi F, Tehrani Banihasheni A et al (2008)
WHO -ILAR COPCORD study(stage 1, urban study) in iran. J Rheumatol
35:1384-90.
19. Veerapen K, WigleyRD, Valkenburg H (2007) musculoskeletal
pain in Malaysia: a COPCORD survey. J Rheumatol 34:207-13.
20. Farooqi A, Gibson T (1998) Prevalence of the major
rheumatic disorders in the adult population of North Pakistan. Br JnRheumatol
37: 491-5.
21. Manahan L, Caragay R, Muirden KD, Allander E, Valkenburg
HA, Wigley RD (1985) Rheumatic pain in a Philippine village.A WHO-ILAR CORPCORD
study. Rheumatol int 5:149-53.
22. Wigley R, Manahan L, Muirden KD et al (1991) Rheumatic
disease in a Philippine village. II: a WHO-ILAR-APLAR COPCORD study, phases II
and III. Rheumaol Int 11:157-61.
23. Dans LF, Tankeh-Torres S, Amante CM, Penserga EG (1997)
the prevalence of rheumatic diseases in a Filipino urban population: a WHO-ILAR
COPCORD study. World Health Organization. International League of Associations
for Rhumatology. Community Oriented Program for control of the Rheumatic
Diseases. J Rhumatol 24:1814-19.
24. Chaiamnuay P, Darmawan J, Muirden KD, Assawatanabodee P
(1998) Epidemiology of Rheumatic disease in rural Tailand: a WHO-ILAR COPCORD
study. Community Oriented Programfor the control of Rheumatic diseases. J
Rheumatol 25:1382-87.
25. Abdel-Nasser A (2004) the prevalence of Rheumatic diseases
in rural Egypt. COPCORD-Egypt. In: APLAR 2004 Proceeding Book, Future in
Rheumatology: From Bench to Bedside, 11th Asia Pacific League of Associations
for Rheumatology Congress, MediMedia, Korea, pp88.
26. Chopra A, Abdel Nasser A (2008) Epidemiology of rheumatic
musculoskeletal disorders in the developing world. Best Pract Res Clin
Rheumatol 22:583-604.
27. Mbuyi-Muamba JM, Tshiani A, Tshiefu K. Etude
rétrospective de quelques maladies rhumatismales aux cliniques
universitaires de Kinshasa, Zaïre. Ann. Soc. belge Med. Trop. 1980,
60,223-6.
28. Mbuyi-Muamba JM, Tshiani A, Nyomba G, Muyembe J, Bloemmen
F, Stevens E. Etude du taux normal du complément dans une population de
Kinshasa, Zaïre. Influence du sexe, de l'âge, et des
périodes de prélèvement des sérums. Ann. Soc. belge
Med. trop. 1980,60, 387-93.
29. Mbuyi-Muamba JM, Tshiani A, Nyomba G, Muyembe T,
Bloemmen, Stevens E. Nephelometric determination of normal serum
immunoglobulin level in adult Bantu from Zaire. Ann. Soc. belge Med trop 1982;
62:253-8.
30. Bwanahali K, MBUYI M, KAPITA B. Arthrose, Goutte et
Polyarthrite Rhumatoïde. Chez des consultants de médecine à
Kinshasa. Revue du Rhumatisme, Févr. 1991.
31. Mbayo K, Mbuyi-Muamba JM, Hallé L, Salmon D,
Martageix C, Castellano F, Kaplan C, Lurhuma Z. HLA-DR Gene Frequencies in a
Zairean Population with Particular Reference to Rhumatic Diseases. Clin
Rhumatol(1998)17:105-9.
32. Malemba JJ, Mbuyi-Muamba JM. Clinical and epidemiological
features of rheumatic diseases in patients attending the university hospital in
Kinshasa. Clin Rheumatol(2008)27:47-54.
33. Goodall, J.W.D. Joint swellings in Africans.
Cent.Afr.J.Med. 1956, 2:220.
34. Hall.L.R.Polyarthritis in Kenya. E.Afr.J.Med.,
1966,43 :161.
35. Gelfand, M. « Medical »arthritis in
African practice. Cent. Afr. J. Med., 169, 15:131.
36. Kanyerezi B.R. Rhumatoid arthritis in Uganda. E.
Afr.Med.J.,1969,46 :71.
37. Kanyerezi B.R, Baddely H and Kisumba D. Rhumatoid
arthritis in Ouganda Africans.Ann. Rhum.Dis. 1970, 29:617.
38. Greenwood, B.M., Polyarthritis in western Nigeria
I.Rheumatoid arthritis. Ann. Rheum. Dis., 1969, 28:488.
39. Beighton, P., Solomon, L. And Valkenburg, H.A., Rheumatoid
arthritis in rural South African Negro Population. Ann. Rheum. Dis., 1975,
34:146.
40. Solomon, L., Beighton, P., Lawrence, J.S. Rheumatic
disorders in the South African Negro. Part II, Osteoarthrosis. S. Afr. Med.
J., 1975, 49:1737.
41. Majiyawa M.A., Djagnikpo A.E., Agbanouvi K, Koumouvi A.,
Agbetra.Maladies rhumatismales observées en Consultation
Hospitalière à Lomé(Togo)
42. Malemba JJ, Mudogo F, Bilonda B .Pathologie
rhumatismales rencontrées chez les jeunes aux cliniques universitaires
de Kinshasa. Ann.Afr.Med.Vol.4.N°2.Mars 2011.
43. Muirden KD, Valkenburg HA, Hopper J, Guest C (1992) the
epidemiology of rheumatic disease in Australia. In: Nasution AR, Darmawan J,
Isbagio H (eds) APLAR rheumatology. Churchill Livingstone, Tokyo, pp
409-410.
44. Haq SA, Rasker JJ, Darmawan J, Chopra A (2008)
WHO-ILAR-COPCORD in the Asia-Pacific: the past, present and future. Int J
Rheum Dis II: 4-10.
45. Van den Bos GAM. The burden of chronic diseases in terms
of disability, use of health care and life expectancies. Eur J Public Health
1995; 5: 29-34.
46. Wigley RD, Zhang NZ, Zeng QY et al (1994) Rheumatic
disease in china: ILAR-China study comparing the prevalence of rheumatic
symptoms in northern ad southern rural populations. J Rheumatol 21:1484-90.
47. Senna ER, De Barros AL,Sylva EO et al. (2004) Prevalence
of Rheumatic diseases in Brazil; a study using COPCORD approach. J Rheumol 31:
594-7.
48. Bennet K, Cardiel MH, Ferraz MB et al. (1997) Community
screening for rhumatic disorder ; cross cultural adaptation and screening
characteristics of the COPCORD . Core Questionnaire in Brazil, Chile, and
Mexico. The PANLAR-COPCORD Working Group.Pan American League of Associations
for rheumatology. Community Oriented Program for Control of Rheumatic Disease.
J Rheumatol 24:160-8.
49. Cofer.Rhumatologie,Abregées,connaissances et
pratiiques. Elsevier -Masson,Paris 2011.
50. Muirden KD,Valkenburg HA,Hopper J,Guest C(1992)The
epidemiology of Rheumatic disease in Australia.In :Nasution AR,Darmawan
J,Isbagio H(eds) APLAR Rheumatiology. Churchil Livingstone, Tokyo, pp409-10.
51. Rasker JJ, Amauts FLJ (2005) the «new»
international league of associations for rheumatology. J Rheumatol 31:
1117-82.
52. Obregon PA, Iraheta I, Garcia-Ferrer H, Garcia-Kutzbach
A. Prevalence of musculoskeletal diseases in Guatemala, central America. The
COPCORD study of 2 populations. J Clini Rheumatol 2012; 18(4):170-4.
53. Znat F,RKain H, Kabbag SE et al. L'origine ethnique aurait
-elle une influence sur le profil de la PR chez le patient Marocain ? rev.
Rhum 2012, (79):A330.
54. Chevalier X, Eymard F, Fichette P. Biologie agents in
osteoarthrits: hopes and disppointment. Nat Rev. Rheumatol 2013 Apr 2.
55. Chevalier X. Osteoarthritis, a disease more complex than
et seems. Rev Prat. 2012, May 62(5) :619-20.
56. Claude Le Pen, Camile Reygrobellet. Les
conséquences socioéconomiques de l'arthrose en France. Revue du
Rhumatisme 72(2005)1326-30.
57. Saroux A. Spondylarthropathies. In Rhumatologie livre de
l'interne 2002, Ed Flammarion Page 272-83.
58. Colebatch AN,Edwards CJ, Ostergaard M et al. Eular
recommandations for the use of imaging of the joints in the clinical
manangement of rheumatoid arthritis. Ann Rheum Dis. 2013, 72 (6):804-14.
59. Chopra A (2004) COPCORD. An unrecognized fountainhead of
community rheumatology in developing countries. J Rheumatol 31:2320-3.
60. Jeandel P, Chouc PY, Laroche. Rhumatologie en Afrique
noir: certitude, perspectives, et inconnues. Médecine d'Afrique
noire : 1991,38(1).
61. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM (2003)
Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis,
and gout in Shanghai, China: a COPCORD study. J Rheumatol 30:2245-51.
62. DiBonaventura et al. Impact of self-rated osteoarthritis
severity in an employed population: cross-sectional analysis of data from the
national health and wellness survey. Health and quality of life outcomes 2012;
10: 30.
63. Fautrel B, Woronoff L; Ethgen M; Fein E; Monnet P; Sibilia
J; Wending D. Impact of medical practices on the costs of manangement of
rheumatoid arthritis by anti-TNF alpha biological therapy in france. Joint Bone
Spine 2005; 72 (6): 550-6.
64. Madland TM, Apalset EM, Johannessen AE et al. Prevalence,
disease manifestations, and treatment of psoriatic arthritis in western Norway.
J Rheumatol 2005; 32:1918-22.
65. Wigley RD, Zhang NZ, Zeng QY et al (1994) Rheumatic
disease in china: ILAR-China study comparing the prevalence of rheumatic
symptoms in northern ad southern rural populations. J Rheumatol 21:1484-90.
66. Dai SM, Han XH, Zhao DB, Shi YQ, Liu Y, Meng JM (2003)
Prevalence of rheumatic symptoms, rheumatoid arthritis, ankylosing spondylitis,
and gout in Shanghai, China: a COPCORD study. J Rheumatol 30:2245-51.
67. Zeng QY, Chen R, Xiao ZY et al (2004) Low prevalence of
knee and back pain in southeast China; the Shantou COPCORD study J Rheumatol
31: 2439-43.
68. Haq SA, Darmawan J, Islam MN et al (2005) Prevalence of
Rheumatic diseases and associated outcomes in rural and urban communities in
Bangladesh: a COPCORD study. J Rheumatol 32:348-53.
69. Darmawan J, Valkenburg HA, Muirden KD, Wigley RD (1992)
Epidemiology of rheumatic diseases in rural and urban populations in Indonesia:
a World Health Organization International League Against Rheumatism COPCORD
study, stage I, phase 2. Ann Rheum Dis 51:525-8.
70. Chopra A, Saluja M, Patil J, Tandale HS (2002) Pain and
disability, perceptions and beliefs of a rural Indian population: A WHO-ILAR
COPCORD study. WHO-International League of Associations for Rheumatology.
Community oriented program for control of rheumatic diseases. J Rheumatol
29:614-21.
71. Forghanizadeh J, Abhari R, Piroozian M et al (1995)
Prevalence of rheumatic disease in Fasham. Journal of Iran University of
Medical Sciences 3:132-42.
72. Davatchi F, Jamshidi AR, Tehrani-Banihashemi A, Darmawan J
(2006) WHO-ILAR COPCORD pilot study in Tehran, Iran. J Rheumatol 33:1714.
73. Davatchi F, Jamshidi AR, Tehrani-Banihashemi A et
al.(2008) WHO-ILAR COPCORD study(stage1,urban study) in iran. J Rheumatol
35:1384-90.
74. Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M.
Predictive factors of rituximab response in rheumatoid arthritis: result from
a French university hospital. Arthritis care Res (Hoboken) 2013 Apr,
65(4):648-52.
75. Veerapen K, WigleyRD, Valkenburg H (2007) musculoskeletal
pain in Malaysia: a COPCORD survey. J Rheumatol 34:207-13.
76. Gerlag DM,Raza K, Van Barsen LGM et al. Eular
recommendations for terminology and researc in individuals at risk of
rheumatoid arthritis report from the study group for risk factor for
rheumatoid arthritis. Ann Rheum Dis 2012;71:638-41
77. Lekpa FK, Ndongo S; Tiendrebeogo J; Ndao AC; Daher A;
Pouye A; Ka MM; Diop TM. Rheumatoid arthritis in Senegal: A comparison between
patients coming from rural and urban areas, in an urban tertiary health care
center in Senegal. Clin Rheumatol 2012; 31 (11): 1617-20.
78. Solomon A, Christian BF; Woodiwiss AJ; Norton GR; Dessein
PH. Burden of depressive symptoms in South African public healthcare patients
with established rheumatoid arthritis: a case-control study. Clin Exp Rheumatol
2011; 29 (3): 506-12.
79. Kaddu MM, Ssekasanvu E, Ddumba E, Thomas D, Katabira ET.
Rheumatoid manifestations among HIV positive adults attending the infectious
desease clinic at Mulago Hospital. Afr Health Sci 2011; 11 (1): 24-9.
80. Prentice AM, Van der Merwe L. Impact of fatty status on
immune function of children in low-income countries. Matern Child Nutr 2011; 7
(2): 89-98.
81. Owonayo O, Houzou P, Koffi-Tessio V, Kodjo K, Fianyo E,
Komi C, Mijiyawa M.Topographic patterns of osteoarthritis of appendicular
joints in patients attending a Teaching Hospital Clinic. La Tunisie
Médicale 2009; 87 (012): 863-6.
82. Strollo R, Ponchel F, Malmstrom V,Rizzo P et al.
Autoantibodies to post translationally modified type II collagen as potential
biomarkers for rheumatoid arthritis. Arthritis Rheum. 2013 Apr10.
83. Ouédraogo DD, Singbo J; Diallo O; Sawadogo SA;
Tiéno H; Drabo YJ. Rheumatoid arthritis in Burkina Faso: Clinical and
serolonigal profiles. Clin Rheumatol 2011; 30 (12): 1617-21.
84. Cui J, Stahai EA, Seavarsdottir S. Miceli C. et al.
Genome-wide association study and gene expression analysis identfies CD84as a
predictor of response to etanercept therapy in rheumatoid arthritis. PLosos
Genet. 2013 Mar; 9(3):e1003394.
85. Ally MM, Hodkinson B, Meyer PW, Musenge E, Tikly M;
Anderson R. Serum matrix metalloproteinase-3 in comparison with acute phase
protein as a maker of disease activity and radiographique damage in early
rheumatoid arthritis. Mediators inflamm 2013, 2013:183653., Epub 2013 Apr 7.
86. Maehlen MT, Provan SA, de Rooy DP, et al. Assocation
between APOE Genotypes and Disease Susceptibility,joint damage and lipid level
in Patients with Rheumatoid Arthritis. PLos One, 2013 Apr 17; 8(4): e 60970.
87. Owino BO, Oyoo GO; Otieno CF. Socio-demographic and
clinical aspects of rheumatoid arthritis. East Afr Med J 2009; 86 (5)
204-11.
88. Ndongo S, Lepka FK; Ka MM; Ndiaye N; Diop TM. Presentation
and severity of rheumatoid arthritis at diagnosis in Senegal. Rheumatology
2009; 48 (9): 1111-3.
89. Solomon A, Chritian BF; Dessein PH. Potentiel determinants
of poor disease outcome in socioeconomically disadvantaged patients with
rheumatoid arthritis. J rheumatol 2008; 35 (9): 1895-6.
90. Schneider M, Manabile E; Tikly M. Social aspects of living
with rheumatoid arthritis: A qualitative descriptive study in Soweto, south
Africa-a low resource context. Health Qual Life Outcome 2008; 24: 6-54.
91. Hodkinson B, Musenge E, Ally M, Meyer PW, Anderson R,
Tikly M. Response to traditional disease-modifying anti-rheumatic drugs in
indigent South Africans with early rheumatoid arthritis. Clin Rheumatol 2012;
31 (4): 613-9.
92. Meyer PW, Hodkinson B, Ally M, Musenge E, Wadee AA, Fickl
H, Tikly M, Anderson R. HLA-DRB1 shared epitope genotyping using the revised
classification and its association with circulating autoantibodies, acute phase
reactants, cytokines and clinical indices of disease activity in a cohort of
south African rheumatoid arthritis patients. Arthritis Res Ther 2011; 13 (5): R
160.
93. Centrola M, Cavet G, Shen Y et al. development of
multi-biomarker disease activity test for rheumatoid arthritis. PLos One.2013
Apr 9;8(4)6063-5
94. Van der Broek M, Visser K, Allaart CE, Huizinga TW.
Personalized medicine: predicting response to therapy in patients with RA.
Curr. Opin.Pharmacol. 2013 Apr.8.
95. Oniankitan O, Ranaivo N, Carton L, Chevalier X,
Claudepierre P. Poorly and well controlled spondylloarthropathies: a comparison
of 2 groups of patients. J Rheumatol 2005; 32 (1): 77-9.
96. Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L,
Chevalier X, Claudepierre P. Estimation of the bath ankylosing spondylitis
disease activity index cutoff for persceived symptom relief in patients with
spondyloarthropathies. J Rheumatol 2006; 33 (1): 79-81.
97. Agbéré AD, Oniankitan I, Mijiyawa MA, Koudou
KS, Koumouvi K, Atakouma DY, Gnamey K, Assimadi K. Epidemiologic and semiologic
profile of juvenile chronic arthritis at the Tokoin University Hospital
Center.Tunis Med 1998; 76 (6-7): 208-11.
98. Mody GM, Brooks PM. Improving musculoskeletal health:
global issues. Best Pract Res Clin Rheumatol 2012; 26 (2): 237-49.
99. Mody GM, Handa R. Preface: Musculoskeletal conditions in
the developing world. Best Pract Clin Rheumatol 2008; 22 (4): 579-81.
100. Oyoo GO, Mody GM. Report on the Fifth African League
Against Rheumatism Congress in Nairobi, Kenya. Clin Rheumatol 2007; 26 (7):
1033-5.
101. Chinniah K, Mody GM, Bhimma R, Adhikari M. Arthritis in
association with human immunodeficiency virus infection in Black African
children: causal or coincidential? Rheumatology (Oxford) 2005; 44 (7):
915-20.
102. Kalla AA, Stanwix A, Gotlieb D, Asherton RA, Mody GM.
Rheumatoid arthritis: clinical guideline 2003. S Afr Med J 2003; 93 (12Pt2):
991-1012.
103. Mody GM, Parke FA, Reveille JD. Articular manifestations
of human immunodeficiency virus infection. Best Pract Clin Rheumatol 2003; 17
(2): 265-87.
104. Grainger AJ,Rowbotham EL Rheumatoid arthritis. Sem
Musculoskelet Radiol 2013 Febr: 17(1) 69-73.
105. Van den Broek M, Dirven L, Kroon HM et al. Early local
swelling and Tenderness Are Associated with Large-joint Damage After 8 years of
treatment to target in Patients with Recent-onset rheumatoid Arthritis. J
Jheumatol 2013 May; 40(5): 624-9.
106. Guillemin F, Briancon S, Klein JM et al. Low incidence
of Rheumatoid arthritis I France. Scand J Reumatol 1994;23:264-8.
107. Colebatch AN, Edwards CJ, Ostergaard M et al. Eular
recommendations for the use of imaging of the joints in the clinical management
of rheumatoid arthritis. Ann Rheum Dis. 2013 juin;72(6):804-14.
108. Davatchi F, Tehrani-Banihashemi A, Gholami J et al. The
prevalence of musculoskeletal complaints in a rural area in Iran: a WHO-ILAR
COPCORD study (stage 1, rural study) in Iran. Clin Rheumatol 2009; 28:
1267-74.
109. Davatchi F, Jamshidi AR, Tehrani-Banihashemi A et al.
Effect of ethnic origin (Caucasians versus Turks) on the prevalence of
rheumatic diseases: a WHO-ILAR COPCORD urban study in iran. Clin Rheumatol
(2009) 28:1275-82.
110. Shilkina NP. Rheumatic diseases and atherosclerosis: a
role of rheological and microcirculatory impairments. Angiol Sosud Khir 2010;
16 (2): 23-9.
111. bAtzeni F, Turiel M, Hollan I, Meroni P, Sitia S,
Tomasoni L, Sarzi-Puttini P. Usefulness of cardiovascular biomarkers and
cardiac imaging in systemic rheumatic diseases. Autoimmun Rev 2010; 9 (12):
845-8.
112. Breland UM, Hollan I, Saatvedt K, Almdahl SM, Damas JK
and al. Inflammatory markers in patients with coronary artery disease with and
without Inflammatory Rheumatic disease. Rheumatology (Oxford) 2010; 49 (6):
1118-27.
113. Yu BL, Wang SH, Peng DQ,, Zhao SP. HDL and
immunomodulation: an emerging role of HDL against atherosclerosis. Immunol cell
Biol 2010; 88 (3): 285-90.
114. Szekanecz Z, Kerekes G, Soltész P. Vascular
effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol
2009; 5 (12): 677-84.
115. Cuellar ML, Espinoza LR. Rheumatic manifestations of
VIH-AIDS. Baillieres Best Pract Res Clin Rheumatol 2000; 14 (3): 579-93.
116. Ekwom PE, Oyoo GO and Ongore D. Prevalance of
musculoskeletal pain in Nairobi, Kenya: results of a phase 1, stage 1 COPCORD
study. SAARA-AFLAR, Durban, Apr 2013, FP3, p20.
117. Trollip S, Njobvu PD, McGill P, Chipeta J and Bucala R.
Spectrum of Rheumatic diseases (RDs) in Lusaka: Then and now. SAARA-AFLAR,
Durban, Apr 2013, FP4, p21
118. Divengi Nzambi JP, Mbuyi-Muamba JM, Malemba JJ.
Tophaceous gout and gender. A report of three cases. SAARA-AFLAR, Durban, Apr
2013, P27, p51.
119. Lukusa Mbaya A, Mbuyi-Muamba JM. Clinical and
radiological profiles of the knee osteoarthritis in the university hospital of
Kinshasa ,DRCongo. SAARA-AFLAR, Durban, Apr 2013, FP41, p36.
120. Lebugue LP, Malemba JJ, Lukusa MA, Divengi JP,Mulumba BC,
Kengibe P, Mboliasa IP, Manyebwa KJD, Amaela NE, Monsere MTet Mbuyi-Muamba JM.
A patway of Rheumatic patient befor consultation to the university hospital of
Kinsahasa SAARA-AFLAR, Durban, Apr 2013, P34, p53.
121. Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Boffuyp X et al.
The phenotype and the genotype of Rhumatoid arthritis in the Democratique
Republic of Congo. SAARA-AFLAR, Durban, Apr 2013, FP2, p20.
122. Divengi-Nzambi JP, Mbuyi-Muamba JM et Malemba JJ. Study
of rheumatoid arthritis prevalence in urban area (Kinshasa) and rural area
(southern Congo) of Democratic Republic of Congo (DRC). SAARA-AFLAR, Durban,
Apr 2013, FP23, p26.
123. Mukaya J and Mbuyi-Muamba. Clinical and radiological
features of lumbar spine stenosis in Congolese patients. SAARA-AFLAR, Durban,
Apr 2013, FP10, p23.
124. Lebughe PL, Malemba JJ, Luzingu JK and Mbuyi-Muamba JM.
Rheumatoid arthritis: Clinical, paraclinical aspects and clinical therapeutic
to the University hospital of Kinshasa. SAARA-AFLAR, Durban, Apr 2013, P21,
p50.
125. Lukusa Mbayo A, Mbuyi Muamba JM and Malemba JJ.
Functional evaluation of Knee osteoarthritis in out patients attending
rheumatology in University hospital, Kinshasa, DR Congo. SAARA-AFLAR, Durban,
Apr 2013, P25, p51.
126. Divengi Nzambi JP, Lukusa Mbaya A, Mulenga C, Mpempele E,
Malemba JJ, Mukaya J, Lelo M, and Mbuyi-Muamba JM. Prevalence of
musculoskeletal disorders in a rural area of the democratic Republic of Congo.
SAARA-AFLAR, Durban, Apr 2013, P33, p53.
127. Malemba JJ, Mbuyi-Muamba JM, Mukaya J, Bossuyt X,
Verschueren P and Westhovens R. First treatment of rheumatoid arthritis with
methotrexate in Congolese patients. SAARA-AFLAR, Durban, Apr 2013, FP40,
p36.
128. Jansen DH, Teunissen T, Van de Lisdonk EH,
L'agro-Janssen ALM. Clinical features of women with gout arthritis.A symetric
review.clin Rheumatol (2010)29:575-82.
129. Roddy E. Doherty M. Epidemiology of gout. Arthritis Res
Ther 2010;12:223.
130. Mounach A, Nouijai A, Ghozlani I, Ghazi M, Achemlal L,
Bezza A, El Maghraoui A. Risk factors for knee osteoarthritis in Morocco. A
case control study. Clin Rheumatol2008; 27: 323-6
131. Spector MD, MacGregor AJ. Risk factors for
osteoarthritis: genetics. Osteoarthritis Cartilage 2004;12(Suppl A):S39-44.
132. Chitnavis J, Sinsheimer JS, Clipsham K, Loughlin J, Sykes
B, Burge PD, et al. Genetic influences in end-stage osteoarthritis.
133. Guillemin F. Epidémiologie des maladies
rhumatismales. Lettre du Rhumatologue-n°266-novembre 2000.
134. Lebughe LP. Profils clinique, biologique et radiologique
des spondylarthropathies en milieu hospitalier de Kinshasa. Mémoire de
fin de spécialisation, UNIKIN, Juin 2013.
135. Reveille JD. Epidemiology of spondylarthritis in North
Amercica, Am J Med sc.2011 april 347,(4): 315-28.
136. Kasapoglu GE, Fatma OS, Kamali S et al. Low frequency of
HLA B27 in Ankylosing spondylithis patients from Turkey, Joint Bone Spine
75(2008) 299-302.
137. Houzou P, Owonayo O, Kodjo K, Viwalé Es, Mijiyawa
M, Profil des affections rhumatismales chez 13517 patients Ouest africain, La
tunisie médicale.2013 vol 91.(n°01) : 16-20.
138. Moustafa M, Owonayo O, Khan MA et al.
Spondylarthropathies in subsahara Africa. Arthritis Rheuma 2002; 46:2968-71.
139. Bela Chew D,Sandu N, Schalla B et al. Ankylosing Spod J
ndylitis in subsaharan Africa, Postgrad med J 2009 Jul; 85(1005):353-7.
140. Mijiyawa M., Ouidrago D, Owanayo O, Khan MA.
Spondylarthropathies in sub-Saharan Africa. Curr opin Rheumatol 2000. 12:
281-6.
141. Wellcome Trust Case Control Consortium. Genome-Wide
association study of 14000 cases of seven common diseases and 3000 shared
controls. Nature 447: 661-78.
142. Cardiel MH,Rojas-Serrano J(2002). Community based study
to estimate prevalence, burden of illness and help seeking behavior in
rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol
20:617-24.
143. Minh Hoa TT, Darmawan J, Chen SL,Van Hung N, Thi Nhi C,
Ngoc An T(2003). Prevalence of the rheumatic diseases in urban Vietnam: a
WHO-ILAR COPCORD study.J Rheumatol. 30:2252-56.
144. Reyes Lierna GA, Guibert Toledano M, Hermandez Martinez
AA, Gonzales Otero ZA, Alcocer Varela J, Cardiel MH(2000). Prevalence of
musculoskeletal complaints and disability in Cuba. A community-based study
using the COPCORD core questionnaire. Clin Exp Rheumatol 18 : 739-42.
145. Gabriel SE, The epidemiology of rheumatoid arthritis.rhem
Dis Clin North Am 2001; 27: 269-81.
146. Silman AJ, Pearson JE.Epidemiology and genetic of
rheumatoid arthritis. Arthritis Res 2002; 4(Suppl 3): 265-72.
147. Lutalo SK. Chronic inflammatory rheumatic diseases in
black Zimbabweans. Ann Rheum Dis 1970; 16: 274-5.
148. Meyers O.L, Daynes G, Beighton O. Rheumatoid arthritis in
a tribal Xhosa population in the Transkei, southern Africa. Ann Rheum Dis, 1977
february; 36: (1):62-5.
149. Malemba JJ, Mbuyi-muambaJM, Mukaya J et al. The
epidemiology of Rhumatoide arthritis in Kinshasa, DRC of Congo-a population
based study. Rheumatology 2012; 51:1644-7.
150. Ministère de la Santé, SEGE. Recueil 2006
du ministère de la santé de la RDC. Kinshasa 2006.
151. Debiais F. ostéoporose. In Rhumatologie, livre de
l'interne, Flammarion, Paris-France .pp 505-21.
152. Shindano T. Le syndrome de l'intestin irritable à
Kinshasa, enquête menée dans deux communes de Kinshasa,
mémoire de fin de spécialisation,UNIKIN, Décembre 2012.
153. Muyer MT, Muls E, Mapatano MA, Makulo JR, et
al.Diabetes and intermediate hyperglycaemia in Kisantu, DR Congo : a
cross-sectional prevalence study.BMJ open 2012. 001911.
| 
